Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Lunsumio Market Growth Potential: How Will Market Size Shift Through 2030?
Historically, expansion was primarily driven by the increasing incidence of Non-Hodgkin Lymphoma, the scarcity of treatment options for recurrent Follicular Lymphoma, a rise in oncology clinical trial endeavors, improvements in antibody engineering methodologies, and regulatory clearances for innovative immunotherapies.
The anticipated expansion during the forecast period is fueled by the broader application of individualized cancer care strategies, the increased uptake of combination immunotherapies, a surge in capital investment directed towards oncology biologics, a heightened demand for cancer treatments delivered in outpatient settings, and persistent advancements in bispecific antibody technology.
Key developments anticipated in the forecast period encompass the expanding utilization of bispecific antibody therapies, an intensifying focus on T-cell engaging immunotherapies, the increasing deployment of precision oncology treatments, the widening availability of targeted interventions for recurring lymphomas, and the strengthened incorporation of biomarker-guided patient selection.
Get A Free Sample Report With In-Depth Market Insights:
Lunsumio Market Growth Momentum: What Factors Are Shaping Demand?
The anticipated growth of the lunsumio market is set to be propelled by the escalating prevalence of blood cancer. Blood cancer refers to malignancies that disrupt the production and function of blood cells, frequently originating in the bone marrow or lymphatic system, with leukemia, lymphoma, and myeloma being among the most common types. The rising incidence of blood cancer can be attributed to an aging population, genetic predisposition, environmental exposures, compromised immune systems, lifestyle choices, and advancements in diagnostic techniques. Lunsumio (mosunetuzumab), a bispecific antibody, effectively treats blood cancers such as lymphoma by specifically targeting and binding to both cancerous B cells and T cells, which empowers the immune system to eradicate these cells. This treatment proves effective in managing diseases characterized by high blood cancer prevalence, offering a viable option for patients with relapsed or refractory conditions. For instance, in 2024, the American Cancer Society, a US-based non-profit cancer advocacy organization, reported that the number of leukemia cases rose to 62,770, an increase from the 59,610 cases recorded in 2023. This data underscores how the increasing prevalence of blood cancer is significantly driving the growth of the lunsumio market.
Lunsumio Market Segment Breakdown: Which Categories Lead On Revenue?
The lunsumio market covered in this report is segmented –
1) By Formulation: Injectable Formulation (Intravenous), Pre-Filled Syringes
2) By Indication: Treatment Of Relapsed Or Refractory FL, Treatment Of Other Non-Hodgkin Lymphomas
3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients With High-Risk Disease Profiles
4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Oncology Clinics, Specialty Pharmacies, Research Institutions
Lunsumio Market Trends Redefining Industry Growth
A notable development within the Lunsumio market centers on pioneering new methods, particularly fixed-duration bispecific antibody therapies, aiming to improve treatment efficacy and expand patient reach. These fixed-duration bispecific antibody therapies are defined as treatments employing dual-targeting antibodies given over a specific, restricted timeframe instead of continuous administration, thereby achieving successful disease management and lessening the burden of extended treatment. An example of this is the launch of LUNSUMIO for Intravenous Infusion (mosunetuzumab) by Chugai Pharmaceutical, a Japan-based oncology/biotech firm, in March 2025, targeting relapsed or refractory follicular lymphoma. This particular therapy is administered as a standalone treatment for patients unsuccessful with two or more previous treatments. It employs a predefined treatment length rather than ongoing therapy to mitigate the long-term treatment load and is engineered to deliver high complete response rates and potentially lasting remission for a patient group that is challenging to treat.
Lunsumio Market Leading Players And Competitive Positioning
Major companies operating in the lunsumio market are Roche Holding AG
View The Full Lunsumio Market Report:
Lunsumio Market Global Footprint: Which Region Leads The Industry?
North America was the largest region in the lunsumio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lunsumio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
